Accès gratuit
Numéro
Med Sci (Paris)
Volume 18, Numéro 6-7, Juin–Juillet 2002
Page(s) 709 - 716
Section M/S Revues : Articles de Synthèse
DOI https://doi.org/10.1051/medsci/20021867709
Publié en ligne 15 juin 2002
  1. Hunter R, Dayan AD, Wilson J. Alzheimer’s disease in one monozygotic twin.J Neurol Neurosurg Psychiatry 1972; 35 : 707–10.
  2. Hardy J. Amyloid, the presenilins and Alzheimer’s disease. Trends Neurosci 1997; 20 : 154–9.
  3. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: highavidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993; 90 : 1977–81.
  4. Chartier-Harlin MC, Parfitt M, Legrain S, et al. Apolipoprotein E, epsilon 4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer’s disease: analysis of the 19q13.2 chromosomal region. Hum Mol Genet 1994; 3 : 569–74.
  5. Bickeboller H, Campion D, Brice A, et al. Apolipoprotein E and Alzheimer disease: genotype-specific risks by age and sex. Am J Hum Genet 1997; 60 : 439–46.
  6. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer disease metaanalysis consortium. JAMA 1997; 278 : 1349–56.
  7. Rao VS, Cupples A, van Duijn CM, et al. Evidence for major gene inheritance of Alzheimer disease in families of patients with and without apolipoprotein E epsilon 4. Am J Hum Genet 1996; 59 : 664–75.
  8. Hardy J. Apolipoprotein E in the genetics and epidemiology of Alzheimer’s disease.Am J Med Genet 1995; 60 : 456–60.
  9. Rebeck GW, Perls TT, West HL, Sodhi P, Lipsitz LA, Hyman BT. Reduced apolipoprotein epsilon 4 allele frequency in the oldest old Alzheimer’s patients and cognitively normal individuals. Neurology 1994; 44 : 1513–6.
  10. Bales KR, Verina T, Dodel RC, et al. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet 1997; 17 : 263–4.
  11. Holtzman DM, Bales KR, Tenkova T, et al. Apolipoprotein E isoformdependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci USA 2000; 97 : 2892–7.
  12. Uchihara T, Duyckaerts C, He Y, et al. ApoE immunoreactivity and microglial cells in Alzheimer’s disease brain. Neurosci Lett 1995; 195 : 5–8.
  13. Aleshkov S, Abraham CR, Zannis VI. Interaction of nascent ApoE2, ApoE3, and ApoE4 isoforms expressed in mammalian cells with amyloid peptide beta (1-40). Relevance to Alzheimer’s disease. Biochemistry 1997; 36 : 10571–80.
  14. Russo C, Angelini G, Dapino D, et al. Opposite roles of apolipoprotein E in normal brains and in Alzheimer’s disease. Proc Natl Acad Sci USA 1998; 95 : 15598–602.
  15. Lambert JC, Perez-Tur J, Dupire MJ, et al. Distortion of allelic expression of apolipoprotein E in Alzheimer’s disease. Hum Mol Genet 1997; 6 : 2151–4.
  16. Bullido MJ, Artiga MJ, Recuero M, et al. A polymorphism in the regulatory region of APOE associated with risk for Alzheimer’s dementia. Nat Genet 1998; 18 : 69–71.
  17. Lambert JC, Pasquier F, Cottel D, Frigard B, Amouyel P, Chartier-Harlin MC. A new polymorphism in the APOE promoter associated with risk of developing Alzheimer’s disease. Hum Mol Genet 1998; 7 : 533–40.
  18. Lambert JC, Araria-Goumidi L, Myllykangas L, et al. Contribution of APOE prmoter polymorphisms to Alzheimer’s disease risk. Neurology 2002 (sous presse).
  19. Artiga MJ, Bullido MJ, Sastre I, et al. Allelic polymorphisms in the transcriptional regulatory region of apolipoprotein E gene. FEBS Lett 1998; 421 : 105–8.
  20. Lambert JC, Berr C, Pasquier F, et al. Pronounced impact of Th1/E47cs mutation compared with -491 AT mutation on neural APOE gene expression and risk of developing Alzheimer’s disease. Hum Mol Genet 1998; 7 : 1511–6.
  21. Lambert JC, Brousseau T, Defosse V, et al. Independent association of an APOE gene promoter polymorphism with increased risk of myocardial infarction and decreased APOE plasma concentrations-the ECTIM study. Hum Mol Genet 2000; 9 : 57–61.
  22. Lambert JC, Mann D, Goumidi L, et al. Effect of the APOE promoter polymorphisms on cerebral amyloid peptide deposition in Alzheimer’s disease. Lancet 2001; 357 : 608–9.
  23. Berr C, Lambert JC, Sazdovitch V, et al. Neuropathological epidemiology of cerebral aging: a study of two genetic polymorphisms. Neurobiol Aging 2001; 22 : 227–35.
  24. Kalmijn S, Launer LJ, Ott A, Witteman JC, Hofman A, Breteler MM. Dietary fat intake and the risk of incident dementia in the Rotterdam study. Ann Neurol 1997; 42 : 776–82.
  25. Wolozin B. A fluid connection: cholesterol and Abeta. Proc Natl Acad Sci USA 2001; 98 : 5371–3.
  26. Mori T, Paris D, Town T, et al. Cholesterol accumulates in senile plaques of Alzheimer disease patients and in transgenic APP(SW) mice. J Neuropathol Exp Neurol 2001; 60 : 778–85.
  27. Refolo LM, Pappolla MA, LaFrancois J, et al. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer’s disease. Neurobiol Dis 2001; 8 : 890–9.
  28. Nathan BP, Bellosta S, Sanan DA, Weisgraber KH, Mahley RW, Pitas RE. Differential effects of apolipoproteins ε3 and ε4 on neuronal growth in vitro. Science 1994; 264 : 850–2.
  29. Poirier J. Apolipoprotein E in animal models of CNS injury and in Alzheimer’s disease. Trends Neurosci 1994; 17 : 525–30.
  30. Egensperger R, Kosel S, von Eitzen U, Graeber MB. Microglial activation in Alzheimer disease: association with APOE genotype. Brain Pathol 1998; 8 : 439–447.
  31. Lomnitski L, Chapman S, Hochman A, et al. Antioxidant mechanisms in apolipoprotein E deficient mice prior to and following closed head injury. Biochim Biophys Acta 1999; 1453 : 359–68.
  32. Barger SW, Mattson MP. Isoform-specific modulation by apolipoprotein E of the activities of secreted beta-amyloid precursor protein.J Neurochem 1997; 69 : 60–7.
  33. Miyata M, Smith JD.Apolipoprotein E allelespecific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet 1996; 14 : 55–61.
  34. Strittmatter WJ, Saunders AM, Goedert M, et al. Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. Proc Natl Acad Sci USA 1994; 91 : 11183–6.
  35. Crutcher KA, Clay MA, Scott SA, Tian X, Tolar M, Harmony JA. Neurite degeneration elicited by apolipoprotein E peptides. Exp Neurol 1994; 130 : 120–6.
  36. Pericak-Vance MA, Bass MP, Yamaoka LH, et al. Complete genomic screen in late-onset familial Alzheimer disease. Evidence for a new locus on chromosome 12. JAMA 1997; 278 : 1237–41.
  37. Rogaeva E, Premkumar S, Song Y, et al. Evidence for an Alzheimer disease susceptibility locus on chromosome 12 and for further locus heterogeneity. JAMA 1998; 280 : 614–8.
  38. Kehoe P, Wavrant-DeVrieze F, Crook R, et al. A full genome scan for late onset Alzheimer’s disease. Hum Mol Genet 1999; 8 : 237–45.
  39. Wu WS, Holmans P, Wavrant-DeVrieze F, et al. Genetic studies on chromosome 12 in late-onset Alzheimer disease. JAMA 1998; 280 : 619–22.
  40. Scott WK, Grubber JM, Conneally PM, et al. Fine mapping of the chromosome 12 late-onset Alzheimer disease locus: potential genetic and phenotypic heterogeneity. Am J Hum Genet 2000; 66 : 922–32.
  41. Lambert JC, Goumidi L, Vrieze FW, et al. The transcriptional factor LBP-1c/CP2/LSF gene on chromosome 12 is a genetic determinant of Alzheimer’s disease. Hum Mol Genet 2000; 9 : 2275–80.
  42. Hu Q, Kukull WA, Bressler SL, et al. The human FE65 gene: genomic structure and an intronic biallelic polymorphism associated with sporadic dementia of the Alzheimer type. Hum Genet 1998; 103 : 295–303.
  43. Cao X, Sudhof TC. A transcriptionally active complex of APP with Fe65 and histone acetyltransferase Tip60. Science 2001; 293 : 115–20.
  44. Koster MN, Dermaut B, Cruts M, et al. The alpha2-macroglobulin gene in AD: a population-based study and meta-analysis. Neurology 2000; 55 : 678–84.
  45. Kang DE, Pietrzik CU, Baum L, et al. Modulation of amyloid beta-protein clearance and Alzheimer’s disease susceptibility by the LDL receptor-related protein pathway. J Clin Invest 2000; 106 : 1159–66.
  46. Majores M, Bagli M, Papassotiropoulos A, et al. Allelic association between the D10S1423 marker and Alzheimer’s disease in a German population. Neurosci Lett 2000; 289 : 224–6.
  47. Zubenko GS, Hughes HB, Stiffler JS, Hurtt MR, Kaplan BB. A genome survey for novel Alzheimer disease risk loci: results at 10-cM resolution. Genomics 1998; 50 : 121–8.
  48. Ertekin-Taner N, Graff-Radford N, Younkin LH, et al. Linkage of plasma Abeta42 to a quantitative locus on chromosome 10 in late-onset Alzheimer’s disease pedigrees. Science 2000; 290 : 2303–4.
  49. Pericak-Vance MA, Grubber J, Bailey LR, et al. Identification of novel genes in late-onset Alzheimer’s disease. Exp Gerontol 2000; 35 : 1343–52.
  50. Myers A, Holmans P, Marshall H, et al. Susceptibility locus for Alzheimer’s disease on chromosome 10. Science 2000; 290 : 2304–5.
  51. Bertram L, Blacker D, Mullin K, et al. Evidence for genetic linkage of Alzheimer’s disease to chromosome 10q. Science 2000; 290 : 2302–3.
  52. Boussaha M, Campion D, Frebourg T. Les protéases impliquées dans la dégradation du peptide Aβ sont-elles des facteurs de risque pour la maladie d’Alzheimer ? Rev Neurol (Paris) 2001; 157 (suppl 10) : 4S10.
  53. Abraham R, Myers A, Wavrant-DeVrieze F, et al. Substantial linkage disequilibrium across the insulin-degrading enzyme locus but no association with late-onset Alzheimer’s disease. Hum Genet 2001; 109 : 646–52.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.